vs

Side-by-side financial comparison of Organogenesis Holdings Inc. (ORGO) and Xperi Inc. (XPER). Click either name above to swap in a different company.

Xperi Inc. is the larger business by last-quarter revenue ($116.5M vs $37.2M, roughly 3.1× Organogenesis Holdings Inc.). On growth, Xperi Inc. posted the faster year-over-year revenue change (-4.8% vs -57.1%). Over the past eight quarters, Xperi Inc.'s revenue compounded faster (-1.0% CAGR vs -46.5%).

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

Xperi Inc. is an American multinational technology company headquartered in San Jose, California, that develops software for consumer electronics and connected cars, as well as media platforms for video service over broadband. The company is organized into four business units: Pay TV, Consumer Electronics, Connected Car, and Media Platform. Xperi's brands include DTS, HD Radio, and TiVo.

ORGO vs XPER — Head-to-Head

Bigger by revenue
XPER
XPER
3.1× larger
XPER
$116.5M
$37.2M
ORGO
Growing faster (revenue YoY)
XPER
XPER
+52.3% gap
XPER
-4.8%
-57.1%
ORGO
Faster 2-yr revenue CAGR
XPER
XPER
Annualised
XPER
-1.0%
-46.5%
ORGO

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ORGO
ORGO
XPER
XPER
Revenue
$37.2M
$116.5M
Net Profit
$-17.1M
Gross Margin
30.8%
Operating Margin
-185.1%
-12.7%
Net Margin
-14.7%
Revenue YoY
-57.1%
-4.8%
Net Profit YoY
-137.0%
EPS (diluted)
$-0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ORGO
ORGO
XPER
XPER
Q1 26
$37.2M
Q4 25
$225.6M
$116.5M
Q3 25
$150.9M
$111.6M
Q2 25
$101.0M
$105.9M
Q1 25
$86.7M
$114.0M
Q4 24
$126.7M
$122.4M
Q3 24
$115.2M
$132.9M
Q2 24
$130.2M
$119.6M
Net Profit
ORGO
ORGO
XPER
XPER
Q1 26
Q4 25
$43.7M
$-17.1M
Q3 25
$21.6M
$-6.1M
Q2 25
$-9.4M
$-14.8M
Q1 25
$-18.8M
$-18.4M
Q4 24
$7.7M
$46.2M
Q3 24
$12.3M
$-16.8M
Q2 24
$-17.0M
$-30.3M
Gross Margin
ORGO
ORGO
XPER
XPER
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
ORGO
ORGO
XPER
XPER
Q1 26
-185.1%
Q4 25
28.1%
-12.7%
Q3 25
13.7%
-1.2%
Q2 25
-12.5%
-10.5%
Q1 25
-30.9%
-14.4%
Q4 24
8.1%
-11.7%
Q3 24
5.4%
-14.0%
Q2 24
-10.7%
-18.3%
Net Margin
ORGO
ORGO
XPER
XPER
Q1 26
Q4 25
19.4%
-14.7%
Q3 25
14.3%
-5.5%
Q2 25
-9.3%
-14.0%
Q1 25
-21.7%
-16.1%
Q4 24
6.1%
37.8%
Q3 24
10.7%
-12.6%
Q2 24
-13.1%
-25.3%
EPS (diluted)
ORGO
ORGO
XPER
XPER
Q1 26
Q4 25
$0.31
$-0.37
Q3 25
$0.11
$-0.13
Q2 25
$-0.10
$-0.32
Q1 25
$-0.17
$-0.41
Q4 24
$0.05
$1.02
Q3 24
$0.09
$-0.37
Q2 24
$-0.13
$-0.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ORGO
ORGO
XPER
XPER
Cash + ST InvestmentsLiquidity on hand
$91.4M
$96.8M
Total DebtLower is stronger
$27.7M
Stockholders' EquityBook value
$414.1M
Total Assets
$520.0M
$615.8M
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ORGO
ORGO
XPER
XPER
Q1 26
$91.4M
Q4 25
$93.7M
$96.8M
Q3 25
$63.7M
$96.8M
Q2 25
$73.1M
$95.1M
Q1 25
$110.0M
$88.0M
Q4 24
$135.6M
$130.6M
Q3 24
$94.3M
$72.7M
Q2 24
$89.9M
$92.5M
Total Debt
ORGO
ORGO
XPER
XPER
Q1 26
Q4 25
$27.7M
Q3 25
$27.7M
Q2 25
$27.7M
Q1 25
$27.7M
Q4 24
$27.7M
Q3 24
$62.3M
$27.7M
Q2 24
$63.8M
$27.7M
Stockholders' Equity
ORGO
ORGO
XPER
XPER
Q1 26
Q4 25
$300.1M
$414.1M
Q3 25
$255.1M
$421.0M
Q2 25
$233.2M
$419.8M
Q1 25
$242.9M
$418.9M
Q4 24
$262.9M
$429.1M
Q3 24
$278.5M
$377.4M
Q2 24
$263.5M
$388.7M
Total Assets
ORGO
ORGO
XPER
XPER
Q1 26
$520.0M
Q4 25
$598.7M
$615.8M
Q3 25
$509.8M
$628.8M
Q2 25
$461.1M
$629.2M
Q1 25
$467.4M
$633.5M
Q4 24
$497.9M
$667.8M
Q3 24
$446.3M
$616.2M
Q2 24
$443.2M
$619.2M
Debt / Equity
ORGO
ORGO
XPER
XPER
Q1 26
Q4 25
0.07×
Q3 25
0.07×
Q2 25
0.07×
Q1 25
0.07×
Q4 24
0.06×
Q3 24
0.22×
0.07×
Q2 24
0.24×
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ORGO
ORGO
XPER
XPER
Operating Cash FlowLast quarter
$4.1M
Free Cash FlowOCF − Capex
$1.2M
FCF MarginFCF / Revenue
1.0%
Capex IntensityCapex / Revenue
2.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-5.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ORGO
ORGO
XPER
XPER
Q1 26
Q4 25
$39.4M
$4.1M
Q3 25
$3.1M
$7.5M
Q2 25
$-32.9M
$10.1M
Q1 25
$-19.9M
$-22.3M
Q4 24
$10.9M
$1.2M
Q3 24
$8.7M
$-4.6M
Q2 24
$4.7M
$-2.1M
Free Cash Flow
ORGO
ORGO
XPER
XPER
Q1 26
Q4 25
$34.8M
$1.2M
Q3 25
$844.0K
$6.7M
Q2 25
$-36.5M
$9.5M
Q1 25
$-23.6M
$-23.3M
Q4 24
$7.6M
$-510.0K
Q3 24
$6.1M
$-5.6M
Q2 24
$2.9M
$-2.6M
FCF Margin
ORGO
ORGO
XPER
XPER
Q1 26
Q4 25
15.4%
1.0%
Q3 25
0.6%
6.0%
Q2 25
-36.1%
9.0%
Q1 25
-27.2%
-20.5%
Q4 24
6.0%
-0.4%
Q3 24
5.3%
-4.2%
Q2 24
2.2%
-2.2%
Capex Intensity
ORGO
ORGO
XPER
XPER
Q1 26
Q4 25
2.1%
2.5%
Q3 25
1.5%
0.7%
Q2 25
3.6%
0.5%
Q1 25
4.2%
0.9%
Q4 24
2.7%
1.4%
Q3 24
2.2%
0.8%
Q2 24
1.4%
0.4%
Cash Conversion
ORGO
ORGO
XPER
XPER
Q1 26
Q4 25
0.90×
Q3 25
0.14×
Q2 25
Q1 25
Q4 24
1.43×
0.03×
Q3 24
0.71×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ORGO
ORGO

Segment breakdown not available.

XPER
XPER

Pay TV$56.2M48%
Connected Car$31.3M27%
Consumer Electronics$17.2M15%
Media Platform$11.8M10%

Related Comparisons